Of note, we show that depletion of BRCA2, while increasing sensitivity to 6-TG in prostate cancer cells, did not affect the response in normal prostate cells, thus implying that other factors, together with BRCA2 levels, are important for modulating the sensitivity to 6-TG specifically in cancer cells. The gene discussed is BRCA2; the disease is prostate carcinoma.